Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,400.96
(
-0.16%
)
US TECH 100
28,206.80
(
-1.14%
)
Dow Jones
49,760.56
(
0.11%
)
Brent Oil
105.19
(
-0.54%
)
Bitcoin
81,012.99
(
0.65%
)
News Focus
News Focus
Post# of 347009
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Protector

Send PM Follow Ignore
Followers 140
Posts 11663
Boards Moderated 0
Alias Born 03/15/2011

Protector

Re: None

Thursday, 01/26/2023 10:29:20 AM

Thursday, January 26, 2023 10:29:20 AM

Post# of 347009
Bavituximab new positive results of clinical trial

From Today: Bavituximab Plus Pembrolizumab Elicits Responses in Untreated Advanced HCC

Jan 25, 2023
By Chris Ryan

see also:

Bavituximab plus pembrolizumab combination achieved a 62.5% response rate in biomarker positive subgroup of hepatocellular cancer patients

Data reinforce the potential of Xerna TME Panel to substantially improve outcomes for patients



And this one also from today

Pembrolizumab Plus Standard Chemotherapy Improves OS in Biliary Tract Cancer

Jan 25, 2023
By Caroline Seymour



AIMO

All In My Opinion. I am not advising anything, nor accusing anyone.

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote